NPJ VaccinesPub Date : 2024-09-10DOI: 10.1038/s41541-024-00949-2
Troy J. Kemp, Gitika Panicker, Carina Eklund, Jianhui Nie, Youchun Wang, Simon Beddows, Peter Rigsby, Weijin Huang, Joakim Dillner, Elizabeth R. Unger, Ligia A. Pinto, Dianna E. Wilkinson
{"title":"WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58","authors":"Troy J. Kemp, Gitika Panicker, Carina Eklund, Jianhui Nie, Youchun Wang, Simon Beddows, Peter Rigsby, Weijin Huang, Joakim Dillner, Elizabeth R. Unger, Ligia A. Pinto, Dianna E. Wilkinson","doi":"10.1038/s41541-024-00949-2","DOIUrl":"https://doi.org/10.1038/s41541-024-00949-2","url":null,"abstract":"<p>Previously established World Health Organization (WHO) International Standards (IS) for anti-HPV16 and HPV18 antibodies are used to harmonize results across human papillomavirus (HPV) serology assays. Here, we present an international collaborative study to establish ISs for antibodies against HPV6 (NIBSC code 19/298), HPV11 (20/174), HPV31 (20/176), HPV33 (19/290), HPV45 (20/178), HPV52 (19/296) and HPV58 (19/300). The candidate standards were prepared using sera from naturally infected individuals. Each candidate was shown to be monospecific for reactivity against its indicated HPV type except for the HPV11 candidate, which was also reactive against other types. Expression of antibody levels relative to the relevant candidate IS reduced inter-laboratory variation allowing greater comparability between laboratories. Based on these results, the WHO Expert Committee on Biological Standardization established each of the 7 candidates as the 1st IS for antiserum to its indicated HPV type for use in the standardization of HPV pseudovirion-based neutralization and antibody-binding assays.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":null,"pages":null},"PeriodicalIF":9.2,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142227908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2024-09-09DOI: 10.1038/s41541-024-00950-9
Sneha Vishwanath, George William Carnell, Martina Billmeier, Luis Ohlendorf, Patrick Neckermann, Benedikt Asbach, Charlotte George, Maria Suau Sans, Andrew Chan, Joey Olivier, Angalee Nadesalingam, Sebastian Einhauser, Nigel Temperton, Diego Cantoni, Joe Grove, Ingo Jordan, Volker Sandig, Paul Tonks, Johannes Geiger, Christian Dohmen, Verena Mummert, Anne Rosalind Samuel, Christian Plank, Rebecca Kinsley, Ralf Wagner, Jonathan Luke Heeney
{"title":"Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants","authors":"Sneha Vishwanath, George William Carnell, Martina Billmeier, Luis Ohlendorf, Patrick Neckermann, Benedikt Asbach, Charlotte George, Maria Suau Sans, Andrew Chan, Joey Olivier, Angalee Nadesalingam, Sebastian Einhauser, Nigel Temperton, Diego Cantoni, Joe Grove, Ingo Jordan, Volker Sandig, Paul Tonks, Johannes Geiger, Christian Dohmen, Verena Mummert, Anne Rosalind Samuel, Christian Plank, Rebecca Kinsley, Ralf Wagner, Jonathan Luke Heeney","doi":"10.1038/s41541-024-00950-9","DOIUrl":"https://doi.org/10.1038/s41541-024-00950-9","url":null,"abstract":"<p>Updates of SARS-CoV-2 vaccines are required to generate immunity in the population against constantly evolving SARS-CoV-2 variants of concerns (VOCs). Here we describe three novel in-silico designed spike-based antigens capable of inducing neutralising antibodies across a spectrum of SARS-CoV-2 VOCs. Three sets of antigens utilising pre-Delta (T2_32), and post-Gamma sequence data (T2_35 and T2_36) were designed. T2_32 elicited superior neutralising responses against VOCs compared to the Wuhan-1 spike antigen in DNA prime-boost immunisation regime in guinea pigs. Heterologous boosting with the attenuated poxvirus - Modified vaccinia Ankara expressing T2_32 induced broader neutralising immune responses in all primed animals. T2_32, T2_35 and T2_36 elicited broader neutralising capacity compared to the Omicron BA.1 spike antigen administered by mRNA immunisation in mice. These findings demonstrate the utility of structure-informed computationally derived modifications of spike-based antigens for inducing broad immune responses covering more than 2 years of evolved SARS-CoV-2 variants.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":null,"pages":null},"PeriodicalIF":9.2,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142227862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2024-09-07DOI: 10.1038/s41541-024-00955-4
Evelyn Tay, Michael Dymock, Laura Lopez, Catherine Glover, Yuanfei Anny Huang, K Shuvo Bakar, Thomas Snelling, Julie A Marsh, Yue Wu
{"title":"Applying causal inference and Bayesian statistics to understanding vaccine safety signals using a simulation study.","authors":"Evelyn Tay, Michael Dymock, Laura Lopez, Catherine Glover, Yuanfei Anny Huang, K Shuvo Bakar, Thomas Snelling, Julie A Marsh, Yue Wu","doi":"10.1038/s41541-024-00955-4","DOIUrl":"10.1038/s41541-024-00955-4","url":null,"abstract":"<p><p>Community perception of vaccine safety influences vaccine uptake. Our objective was to assess current vaccine safety monitoring by examining factors that may influence the availability of post-vaccination survey data, and thereby the specificity and sensitivity of existing signal detection methods. We used causal directed acyclic graphs (DAGs) and a Bayesian posterior predictive analysis (PPA) signal detection method to understand biological and behavioural factors which may influence signal detection. The DAGs informed the data simulated for scenarios in which these factors were varied. The influence of biological factors such as severity of adverse reactions and behavioural factors such as healthcare-seeking behaviour upon survey participation was found to drive signal detection. Where there was a low prevalence of moderate to severe reactions, false signals were detected when there was a strong influence of reaction severity on both survey participation and seeking medical attention. These findings provide implications for future vaccine safety monitoring.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2024-09-05DOI: 10.1038/s41541-024-00944-7
Cynthia Calzas, Tamiru N Alkie, Matthew Suderman, Carissa Embury-Hyatt, Vinay Khatri, Ronan Le Goffic, Yohannes Berhane, Steve Bourgault, Denis Archambault, Christophe Chevalier
{"title":"M2e nanovaccines supplemented with recombinant hemagglutinin protect chickens against heterologous HPAI H5N1 challenge.","authors":"Cynthia Calzas, Tamiru N Alkie, Matthew Suderman, Carissa Embury-Hyatt, Vinay Khatri, Ronan Le Goffic, Yohannes Berhane, Steve Bourgault, Denis Archambault, Christophe Chevalier","doi":"10.1038/s41541-024-00944-7","DOIUrl":"10.1038/s41541-024-00944-7","url":null,"abstract":"<p><p>Current poultry vaccines against influenza A viruses target the globular head region of the hemagglutinin (HA1), providing limited protection against antigenically divergent strains. Experimental subunit vaccines based on the conserved ectodomain of the matrix protein 2 (M2e) induce cross-reactive antibody responses, but fail to fully prevent virus shedding after low pathogenic avian influenza (LPAI) virus challenge, and are ineffective against highly pathogenic avian influenza (HPAI) viruses. This study assessed the benefits of combining nanoparticles bearing three tandem M2e repeats (NR-3M2e nanorings or NF-3M2e nanofilaments) with an HA1 subunit vaccine in protecting chickens against a heterologous HPAI H5N1 virus challenge. Chickens vaccinated with the combined formulations developed M2e and HA1-specific antibodies, were fully protected from clinical disease and mortality, and showed no histopathological lesions or virus shedding, unlike those given only HA1, NR-3M2e, or NF-3M2e. Thus, the combined vaccine formulations provided complete cross-protection against HPAI H5N1 virus, and prevented environmental virus shedding, crucial for controlling avian influenza outbreaks.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11377767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142140678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2024-09-04DOI: 10.1038/s41541-024-00957-2
Renee L Hajnik, Jessica A Plante, Srinivasa Reddy Bonam, Grace H Rafael, Yuejin Liang, Nicholas C Hazell, Jordyn Walker, Rachel A Reyna, David H Walker, Mohamad-Gabriel Alameh, Drew Weissman, Scott C Weaver, Kenneth S Plante, Haitao Hu
{"title":"Broad protection and respiratory immunity of dual mRNA vaccination against SARS-CoV-2 variants.","authors":"Renee L Hajnik, Jessica A Plante, Srinivasa Reddy Bonam, Grace H Rafael, Yuejin Liang, Nicholas C Hazell, Jordyn Walker, Rachel A Reyna, David H Walker, Mohamad-Gabriel Alameh, Drew Weissman, Scott C Weaver, Kenneth S Plante, Haitao Hu","doi":"10.1038/s41541-024-00957-2","DOIUrl":"10.1038/s41541-024-00957-2","url":null,"abstract":"<p><p>While first-generation, spike (S)-based COVID-19 vaccines were effective against early SARS-CoV-2 strains, the rapid evolution of novel Omicron subvariants have substantially reduced vaccine efficacy. As such, broadly protective vaccines against SARS-CoV-2 are needed to prevent future viral emergence. In addition, it remains less clear whether peripheral immunization, especially with mRNA vaccines, elicits effective respiratory immunity. Our group has developed a nucleoside-modified mRNA vaccine expressing the nucleocapsid (N) protein of the ancestral SARS-CoV-2 virus and has tested its use in combination with the S-based mRNA vaccine (mRNA-S). In this study, we examined efficacy of mRNA-N alone or in combination with mRNA-S (mRNA-S+N) against more immune evasive Omicron variants in hamsters. Our data show that mRNA-N alone induces a modest but significant protection against BA.5 and that dual mRNA-S+N vaccination confers complete protection against both BA.5 and BQ.1, preventing detection of virus in the hamster lungs. Analysis of respiratory immune response in mice shows that intramuscular mRNA-S+N immunization effectively induces respiratory S- and N-specific T cell responses in the lungs and in bronchoalveolar lavage (BAL), as well as antigen-specific binding IgG in BAL. Together, our data further support mRNA-S+N as a potential pan-COVID-19 vaccine for broad protection against current and emerging SARS-CoV-2 variants.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142133280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2024-09-01DOI: 10.1038/s41541-024-00953-6
Rochelle M Da Costa, Jessica L Rooke, Timothy J Wells, Adam F Cunningham, Ian R Henderson
{"title":"Type 5 secretion system antigens as vaccines against Gram-negative bacterial infections.","authors":"Rochelle M Da Costa, Jessica L Rooke, Timothy J Wells, Adam F Cunningham, Ian R Henderson","doi":"10.1038/s41541-024-00953-6","DOIUrl":"10.1038/s41541-024-00953-6","url":null,"abstract":"<p><p>Infections caused by Gram-negative bacteria are leading causes of mortality worldwide. Due to the rise in antibiotic resistant strains, there is a desperate need for alternative strategies to control infections caused by these organisms. One such approach is the prevention of infection through vaccination. While live attenuated and heat-killed bacterial vaccines are effective, they can lead to adverse reactions. Newer vaccine technologies focus on utilizing polysaccharide or protein subunits for safer and more targeted vaccination approaches. One promising avenue in this regard is the use of proteins released by the Type 5 secretion system (T5SS). This system is the most prevalent secretion system in Gram-negative bacteria. These proteins are compelling vaccine candidates due to their demonstrated protective role in current licensed vaccines. Notably, Pertactin, FHA, and NadA are integral components of licensed vaccines designed to prevent infections caused by Bordetella pertussis or Neisseria meningitidis. In this review, we delve into the significance of incorporating T5SS proteins into licensed vaccines, their contributions to virulence, conserved structural motifs, and the protective immune responses elicited by these proteins.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11366766/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142109976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2024-08-31DOI: 10.1038/s41541-024-00954-5
Dan Zhou, Rao Cheng, Yanfeng Yao, Gan Zhang, Xin Li, Bingjie Wang, Yong Wang, Feiyang Yu, Shangyu Yang, Hang Liu, Ge Gao, Yun Peng, Miaoyu Chen, Zengqin Deng, Haiyan Zhao
{"title":"An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection.","authors":"Dan Zhou, Rao Cheng, Yanfeng Yao, Gan Zhang, Xin Li, Bingjie Wang, Yong Wang, Feiyang Yu, Shangyu Yang, Hang Liu, Ge Gao, Yun Peng, Miaoyu Chen, Zengqin Deng, Haiyan Zhao","doi":"10.1038/s41541-024-00954-5","DOIUrl":"10.1038/s41541-024-00954-5","url":null,"abstract":"<p><p>Nipah virus (NiV) is a zoonotic emergent paramyxovirus that can cause severe encephalitis and respiratory infections in humans, with a high fatality rate ranging from 40% to 75%. Currently, there are no approved human vaccines or antiviral drugs against NiV. Here, we designed a ferritin-based self-assembling nanoparticle displaying the NiV G head domain on the surface (NiV G-ferritin) and assessed immune responses elicited by the soluble NiV G head domain (NiV sG) or NiV G-ferritin. Immunization with NiV G-ferritin or NiV sG conferred complete protection against lethal NiV challenge without detection of viral RNA in Syrian golden hamsters. Compared to NiV sG, NiV G-ferritin induced significantly faster, broader, and higher serum neutralizing responses against three pathogenic henipaviruses (NiV-Malaysia, NiV-Bangladesh, and Hendra virus). Moreover, NiV G-ferritin induced a durable neutralizing immunity in mice as antisera potently inhibited NiV infection even after six months of the third immunization. Additionally, we isolated a panel of 27 NiV G-binding monoclonal antibodies (mAbs) from NiV G-ferritin immunized mice and found that these mAbs targeted four distinct antigenic sites on NiV G head domain with two sites that have not been defined previously. Notably, 25 isolated mAbs have potent neutralizing activity with 50% inhibitory concentrations less than 10 ng/mL against NiV pseudovirus. Collectively, these findings provide new insights into the immunogenicity of NiV G protein and reveal that NiV G-ferritin is a safe and highly effective vaccine candidate against Nipah virus infection.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11365981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142109975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2024-08-28DOI: 10.1038/s41541-024-00927-8
Amanda J Martinot, Freek Cox, Peter Abbink, Jonathan L Hecht, Roderick Bronson, Erica N Borducchi, William J Rinaldi, Melissa J Ferguson, Rafael A De La Barrera, Roland Zahn, Leslie van der Fits, Dan H Barouch
{"title":"Ad26.M.Env ZIKV vaccine protects pregnant rhesus macaques and fetuses against Zika virus infection.","authors":"Amanda J Martinot, Freek Cox, Peter Abbink, Jonathan L Hecht, Roderick Bronson, Erica N Borducchi, William J Rinaldi, Melissa J Ferguson, Rafael A De La Barrera, Roland Zahn, Leslie van der Fits, Dan H Barouch","doi":"10.1038/s41541-024-00927-8","DOIUrl":"https://doi.org/10.1038/s41541-024-00927-8","url":null,"abstract":"<p><p>At the start of the Zika virus (ZIKV) epidemic in 2015, ZIKV spread across South and Central America, and reached parts of the southern United States placing pregnant women at risk for fetal microcephaly, fetal loss, and other adverse pregnancy outcomes associated with congenital ZIKA syndrome (CZS). For this reason, testing of a safe and efficacious ZIKV vaccine remains a global health priority. Here we report that a single immunization with Ad26.M.Env ZIKV vaccine, when administered prior to conception, fully protects pregnant rhesus macaques from ZIKV viral RNA in blood and tissues with no adverse effects in dams and fetuses. Furthermore, vaccination prevents ZIKV distribution to fetal tissues including the brain. ZIKV associated neuropathology was absent in offspring of Ad26.M.Env vaccinated dams, although pathology was limited in fetuses from non-immunized, challenged dams. Vaccine efficacy is associated with induction of ZIKV neutralizing antibodies in pregnant rhesus macaques. These data suggest the feasibility of vaccine prevention of CZS in humans.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11358461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142093645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ VaccinesPub Date : 2024-08-28DOI: 10.1038/s41541-024-00946-5
Rebecca Clarke, Tehmina Bharucha, Benediktus Yohan Arman, Bevin Gangadharan, Laura Gomez Fernandez, Sara Mosca, Qianqi Lin, Kerlijn Van Assche, Robert Stokes, Susanna Dunachie, Michael Deats, Hamid A Merchant, Céline Caillet, John Walsby-Tickle, Fay Probert, Pavel Matousek, Paul N Newton, Nicole Zitzmann, James S O McCullagh
{"title":"Using matrix assisted laser desorption ionisation mass spectrometry combined with machine learning for vaccine authenticity screening.","authors":"Rebecca Clarke, Tehmina Bharucha, Benediktus Yohan Arman, Bevin Gangadharan, Laura Gomez Fernandez, Sara Mosca, Qianqi Lin, Kerlijn Van Assche, Robert Stokes, Susanna Dunachie, Michael Deats, Hamid A Merchant, Céline Caillet, John Walsby-Tickle, Fay Probert, Pavel Matousek, Paul N Newton, Nicole Zitzmann, James S O McCullagh","doi":"10.1038/s41541-024-00946-5","DOIUrl":"10.1038/s41541-024-00946-5","url":null,"abstract":"<p><p>The global population is increasingly reliant on vaccines to maintain population health with billions of doses used annually in immunisation programmes. Substandard and falsified vaccines are becoming more prevalent, caused by both the degradation of authentic vaccines but also deliberately falsified vaccine products. These threaten public health, and the increase in vaccine falsification is now a major concern. There is currently no coordinated global infrastructure or screening methods to monitor vaccine supply chains. In this study, we developed and validated a matrix-assisted laser desorption/ionisation-mass spectrometry (MALDI-MS) workflow that used open-source machine learning and statistical analysis to distinguish authentic and falsified vaccines. We validated the method on two different MALDI-MS instruments used worldwide for clinical applications. Our results show that multivariate data modelling and diagnostic mass spectra can be used to distinguish authentic and falsified vaccines providing proof-of-concept that MALDI-MS can be used as a screening tool to monitor vaccine supply chains.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":null,"pages":null},"PeriodicalIF":6.9,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11358428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142094436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
